Identification of potent indolizine derivatives against Mycobacterial tuberculosis: In vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies
Katharigatta N. Venugopala
1, 2
,
Sandeep Chandrashekharappa
3
,
Pran Kishore Deb
4
,
Nizar A. Al-Shar'i
5, 6
,
Melendhran Pillay
7
,
Priya Tiwari
3
,
Deepak Chopra
8
,
Pobitra Borah
9
,
Rasoul Tamhaev
10, 11
,
Lionel Mourey
10
,
Christian Lherbet
11
,
Bandar E. Aldhubiab
2
,
Bandar Aldhubiab
2
,
Christophe Tratrat
2
,
Mahesh Attimarad
2
,
Anroop B. Nair
2
,
Nagaraja Sreeharsha
2, 12
,
Raghu Prasad Mailavaram
13
,
Rashmi Venugopala
14
,
Viresh Mohanlall
1
,
Mohamed A Morsy
2, 15
,
Mohamed M. Morsy
2, 15
12
Department of Pharmaceutics, Vidya Siri College of Pharmacy, Off Sarjapura Road, Bangalore 560035, India
|
13
Department of Pharmaceutical Chemistry, Shri Vile Parle Kelavani Mandal's Institute of Pharmacy, Samtanagar, Dhule 424 001, Maharashtra, India
|
Publication type: Journal Article
Publication date: 2024-08-01
scimago Q1
wos Q1
SJR: 1.285
CiteScore: 10.3
Impact factor: 8.5
ISSN: 01418130, 18790003
PubMed ID:
38925196
Abstract
In the current study, two sets of compounds: (E)-1-(2-(4-substitutedphenyl)-2-oxoethyl)-4-((hydroxyimino)methyl)pyridinium derivatives (3a-3e); and (E)-3-(substitutedbenzoyl)-7-((hydroxyimino)methyl)-2-substitutedindolizine-1-carboxylate derivatives (5a-5j), were synthesized and biologically evaluated against two strains of Mycobacterial tuberculosis (ATCC 25177) and multi-drug resistant (MDR) strains. Further, they were also tested in vitro against the mycobacterial InhA enzyme. The in vitro results showed excellent inhibitory activities against both MTB strains and compounds 5a-5j were found to be more potent, and their MIC values ranged from 5 to 16 μg/mL and 16-64 μg/mL against the M. tuberculosis (ATCC 25177) and MDR-TB strains, respectively. Compound 5h with phenyl and 4-fluorobenzoyl groups attached to the 2- and 3-position of the indolizine core was found to be the most active against both strains with MIC values of 5 μg/mL and 16 μg/mL, respectively. On the other hand, the two sets of compounds showed weak to moderate inhibition of InhA enzyme activity that ranged from 5 to 17 % and 10-52 %, respectively, with compound 5f containing 4-fluoro benzoyl group attached to the 3-position of the indolizine core being the most active (52 % inhibition of InhA). Unfortunately, there was no clear correlation between the InhA inhibitory activity and MIC values of the tested compounds, indicating the probability that they might have different modes of action other than InhA inhibition. Therefore, a computational investigation was conducted by employing molecular docking to identify their putative drug target(s) and, consequently, understand their mechanism of action. A panel of 20 essential mycobacterial enzymes was investigated, of which β-ketoacyl acyl carrier protein synthase I (KasA) and pyridoxal-5'-phosphate (PLP)-dependent aminotransferase (BioA) enzymes were revealed as putative targets for compounds 3a-3e and 5a-5j, respectively. Moreover, in silico ADMET predictions showed adequate properties for these compounds, making them promising leads worthy of further optimization.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
|
|
|
Journal of Molecular Structure
2 publications, 25%
|
|
|
Medicinal Research Reviews
1 publication, 12.5%
|
|
|
Organic Chemistry Frontiers
1 publication, 12.5%
|
|
|
European Journal of Medicinal Chemistry
1 publication, 12.5%
|
|
|
Journal of Biomolecular Structure and Dynamics
1 publication, 12.5%
|
|
|
ACS Applied Bio Materials
1 publication, 12.5%
|
|
|
Organic and Biomolecular Chemistry
1 publication, 12.5%
|
|
|
1
2
|
Publishers
|
1
2
3
|
|
|
Elsevier
3 publications, 37.5%
|
|
|
Royal Society of Chemistry (RSC)
2 publications, 25%
|
|
|
Wiley
1 publication, 12.5%
|
|
|
Taylor & Francis
1 publication, 12.5%
|
|
|
American Chemical Society (ACS)
1 publication, 12.5%
|
|
|
1
2
3
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
8
Total citations:
8
Citations from 2024:
8
(100%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Venugopala K. N. et al. Identification of potent indolizine derivatives against Mycobacterial tuberculosis: In vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies // International Journal of Biological Macromolecules. 2024. Vol. 274. No. Pt 2. p. 133285.
GOST all authors (up to 50)
Copy
Venugopala K. N. et al. Identification of potent indolizine derivatives against Mycobacterial tuberculosis: In vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies // International Journal of Biological Macromolecules. 2024. Vol. 274. No. Pt 2. p. 133285.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1016/j.ijbiomac.2024.133285
UR - https://linkinghub.elsevier.com/retrieve/pii/S014181302404090X
TI - Identification of potent indolizine derivatives against Mycobacterial tuberculosis: In vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies
T2 - International Journal of Biological Macromolecules
AU - Venugopala, Katharigatta N.
AU - Chandrashekharappa, Sandeep
AU - Deb, Pran Kishore
AU - Al-Shar'i, Nizar A.
AU - Pillay, Melendhran
AU - Tiwari, Priya
AU - Chopra, Deepak
AU - Borah, Pobitra
AU - Tamhaev, Rasoul
AU - Mourey, Lionel
AU - Lherbet, Christian
AU - Aldhubiab, Bandar E.
AU - Aldhubiab, Bandar
AU - Tratrat, Christophe
AU - Attimarad, Mahesh
AU - Nair, Anroop B.
AU - Sreeharsha, Nagaraja
AU - Mailavaram, Raghu Prasad
AU - Venugopala, Rashmi
AU - Mohanlall, Viresh
AU - Morsy, Mohamed A
AU - Morsy, Mohamed M.
PY - 2024
DA - 2024/08/01
PB - Elsevier
SP - 133285
IS - Pt 2
VL - 274
PMID - 38925196
SN - 0141-8130
SN - 1879-0003
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2024_Venugopala,
author = {Katharigatta N. Venugopala and Sandeep Chandrashekharappa and Pran Kishore Deb and Nizar A. Al-Shar'i and Melendhran Pillay and Priya Tiwari and Deepak Chopra and Pobitra Borah and Rasoul Tamhaev and Lionel Mourey and Christian Lherbet and Bandar E. Aldhubiab and Bandar Aldhubiab and Christophe Tratrat and Mahesh Attimarad and Anroop B. Nair and Nagaraja Sreeharsha and Raghu Prasad Mailavaram and Rashmi Venugopala and Viresh Mohanlall and Mohamed A Morsy and Mohamed M. Morsy and others},
title = {Identification of potent indolizine derivatives against Mycobacterial tuberculosis: In vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies},
journal = {International Journal of Biological Macromolecules},
year = {2024},
volume = {274},
publisher = {Elsevier},
month = {aug},
url = {https://linkinghub.elsevier.com/retrieve/pii/S014181302404090X},
number = {Pt 2},
pages = {133285},
doi = {10.1016/j.ijbiomac.2024.133285}
}
Cite this
MLA
Copy
Venugopala, Katharigatta N., et al. “Identification of potent indolizine derivatives against Mycobacterial tuberculosis: In vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies.” International Journal of Biological Macromolecules, vol. 274, no. Pt 2, Aug. 2024, p. 133285. https://linkinghub.elsevier.com/retrieve/pii/S014181302404090X.